Telescope Innovations Corp. develops manufacturing processes and tools for the pharmaceutical and chemical industries in the U.S. and Canada. The company boasts a strong gross margin of 100%, indicating effective cost management, but faces significant concerns with negative EBITDA and net margins, reflecting operational challenges. While its liquidity ratios are solid, suggesting good short-term financial health, the negative return metrics raise questions about long-term profitability. The high gross margin juxtaposed with low valuation may imply potential but also highlights the need for improved operational efficiency.
Loading financial metrics...
Company has $1.3M in cash but burned $1.4M last quarter. At this burn rate, only 0.9 quarters of runway remain without additional financing.
Company posted a loss of $-4.1M over the last year, representing 43.7% of revenue.
Exceptional revenue growth of 150.6% YoY demonstrates strong market demand and competitive positioning.
Operating margin expanded by 14.9pp, demonstrating strong operational leverage.
Exceptional gross margin of 69.1% indicates strong pricing power and competitive moat.
Excellent liquidity with current ratio of 2.6x ensures operational stability.
Low debt-to-revenue ratio of 29.0% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q3 (May 31, 2026)